Report Detail
Drug analysis: Lumateperone
     Published : April  - 2018  | Format : PDF  | Pages : 25
Single User Price : $10,000   
Site License  
Global Site License$49,000  
Description Table of Contents List of Tables List of FiguresCompanies Mentioned

"Drug Overview Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modulator of the dopaminergic and glutamatergic systems, and a serotonin reuptake inhibitor. By targeting the serotonergic and dopaminergic systems, the drug appears to reduce agitation and minimize positive symptoms. Its additional actions on glutamatergic signaling are believed to help address both negative and cognitive schizophrenia symptoms.

Intra-Cellular Therapies licensed lumateperone from its original developer, Bristol-Myers Squibb, in 2005, and is now solely responsible for the drug’s development. In December 2015, the company announced the initiation of patient enrollment for its two Phase III trials in bipolar depression. Additional clinical programs with lumateperone include its Phase III development in schizophrenia and behavioral disturbances in dementia."

Published byDMH         
© 2011 Omen Market Solutions All rights reserved. Home| About Us | Reports Repository | Services & Subscriptions l  Publishers l  Contact Us